Pparg-KO Mouse
Common Name
Pparg-KO
제품 ID
S-KO-03748
Backgroud
C57BL/6JCya
품종 계통계통 ID
KOCMP-19016-Pparg-B6J-VB
상태
이 마우스 계통을 논문에서 사용할 경우, “Pparg-KO Mouse (카탈로그 번호 S-KO-03748)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Pparg-KO
품종 계통계통 ID
KOCMP-19016-Pparg-B6J-VB
유전자명
제품 ID
S-KO-03748
유전자 별칭
Nr1c3, PPARgamma, PPAR-gamma, PPARgamma2, PPAR-gamma2
배경
C57BL/6JCya
NCBI ID
변형 내용
Conventional knockout
염색체
Chr 6
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000000450
NCBI 전사체 ID
NM_011146.3
타겟 영역
Exon 4
유효 영역 크기
~1.1 kb
유전자 연구 개요
Pparg, peroxisome proliferator-activated receptor gamma, is a receptor crucial for controlling cellular metabolism. It regulates the function of immune and stromal cells and is involved in multiple biological processes, such as anti-inflammatory and neuroprotective pathways, as well as lipid and glucose metabolism [1,2]. Genetic studies on its polymorphisms have been used to explore its role in diseases [4-6].
In rheumatoid arthritis (RA), PPARG promotes autophagy to accelerate reactive oxygen species (ROS) clearance, inhibiting ROS-mediated macrophage polarization and NLRP3 inflammasome activation, thus alleviating inflammation. CBD can act as a PPARG agonist to mitigate RA's inflammatory progression [1]. In major depression, the PPARg system has anti-inflammatory and neuroprotective effects in the CNS, increasing BDNF levels, promoting neuroplasticity and neurogenesis, and potentially having antidepressant effects [2]. In adrenal Cushing's syndrome, PPARG and related genes are downregulated, and its activator rosiglitazone decreases cell viability and steroid production, suggesting its potential as a therapeutic target [3]. For type 2 diabetes mellitus (T2DM), the rs1801282 (Pro12Ala) variant in PPARG is associated with a decreased risk of T2DM, and patients with the Ala12 variant may respond better to thiazolidinediones treatment [4,5]. In bladder cancer, Pparg signaling controls cancer subtype and immune exclusion, being downregulated in basal (muscle-invasive) and amplified in luminal (non-muscle-invasive) subtypes [6]. In psoriasis vulgaris, enhanced PPARG gene expression is a protective factor, indicating it as a potential therapeutic target [7]. In hypopharyngeal squamous cell carcinoma (HSCC), PPARG may promote chemosensitivity, likely by affecting cell proliferation and motility pathways [8].
In summary, Pparg plays essential roles in multiple biological processes and disease conditions. Studies on its genetic variants and functions in various disease models, especially in relation to inflammation, metabolism, and cancer, have provided insights into potential therapeutic strategies targeting Pparg.
References:
1. Geng, Qishun, Xu, Jiahe, Cao, Xiaoxue, Jia, Lansi, Xiao, Cheng. 2024. PPARG-mediated autophagy activation alleviates inflammation in rheumatoid arthritis. In Journal of autoimmunity, 146, 103214. doi:10.1016/j.jaut.2024.103214. https://pubmed.ncbi.nlm.nih.gov/38648706/
2. Gold, Philip W. 2021. The PPARg System in Major Depression: Pathophysiologic and Therapeutic Implications. In International journal of molecular sciences, 22, . doi:10.3390/ijms22179248. https://pubmed.ncbi.nlm.nih.gov/34502154/
3. Vetrivel, Sharmilee, Tamburello, Mariangela, Oßwald, Andrea, Sbiera, Silviu, Riester, Anna. 2023. PPARG dysregulation as a potential molecular target in adrenal Cushing's syndrome. In Frontiers in endocrinology, 14, 1265794. doi:10.3389/fendo.2023.1265794. https://pubmed.ncbi.nlm.nih.gov/38098864/
4. Sarhangi, Negar, Sharifi, Farshad, Hashemian, Leila, Aghaei Meybodi, Hamid Reza, Hasanzad, Mandana. 2020. PPARG (Pro12Ala) genetic variant and risk of T2DM: a systematic review and meta-analysis. In Scientific reports, 10, 12764. doi:10.1038/s41598-020-69363-7. https://pubmed.ncbi.nlm.nih.gov/32728045/
5. Jang, Eun Jeong, Lee, Da Hoon, Im, Sae-Seul, Yee, Jeong, Gwak, Hye Sun. 2023. Correlation between PPARG Pro12Ala Polymorphism and Therapeutic Responses to Thiazolidinediones in Patients with Type 2 Diabetes: A Meta-Analysis. In Pharmaceutics, 15, . doi:10.3390/pharmaceutics15061778. https://pubmed.ncbi.nlm.nih.gov/37376225/
6. Tate, Tiffany, Xiang, Tina, Wobker, Sarah E, Mckiernan, James M, Mendelsohn, Cathy Lee. 2021. Pparg signaling controls bladder cancer subtype and immune exclusion. In Nature communications, 12, 6160. doi:10.1038/s41467-021-26421-6. https://pubmed.ncbi.nlm.nih.gov/34697317/
7. Xue, Yan, Xia, Yuning, Cheng, Donghao, Mei, Ping, Hong, Sheng. 2024. Association between genetically proxied PPARG activation and psoriasis vulgaris: a Mendelian randomization study. In The Journal of dermatological treatment, 35, 2381763. doi:10.1080/09546634.2024.2381763. https://pubmed.ncbi.nlm.nih.gov/39034037/
8. Lian, Meng, Chen, Jiaming, Shen, Xixi, Hou, Lizhen, Fang, Jugao. 2020. Pparg may Promote Chemosensitivity of Hypopharyngeal Squamous Cell Carcinoma. In PPAR research, 2020, 6452182. doi:10.1155/2020/6452182. https://pubmed.ncbi.nlm.nih.gov/32373170/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.